SCM
BIOTU

Shaolin Capital Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Shaolin Capital Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-106,888
Closed -$1.07M – 804
2021
Q3 		$1.07M Hold
106,888
– – 0.03% 330
2021
Q2 		$1.08M Buy
106,888
+6,888
+7% +$69K 0.03% 338
2021
Q1 		$989K Buy
+100,000
New +$1.03M 0.04% 343

Other funds holding BIOTU

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 33.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Shaolin Capital Management's BIOTU Position: Q4 2021 in Review

Shaolin Capital Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2021, closing a stake of 106,888 shares — an estimated $1.07M sold.

Shaolin Capital Management first reported a position in BIOTU in Q1 2021 and held it in 3 quarters. The position peaked at $1.08M in Q2 2021. 15 funds tracked by Wall St. Rank hold BIOTU as of Q4 2021.

  • Shaolin Capital Management reported no remaining Biotech Acquisition Company Unit position as of Q4 2021 after selling out during the quarter.
  • Shaolin Capital Management sold 106,888 Biotech Acquisition Company Unit shares in Q4 2021, an estimated $1.07M.
  • Shaolin Capital Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 3 quarters.
  • Shaolin Capital Management's Biotech Acquisition Company Unit position peaked at $1.08M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2021.

Based on Shaolin Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.